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Figure 1. A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in vitro. (A) Western blot
analysis showing p63 expression in a panel of 12 human PDA cell lines. (B–C) Bar charts show expression of TP63 and KRT5 cell lines shown in (A). (D)
Schematic of experimental workflow for RNA-seq analysis of PSCs following culture in Matrigel with conditioned media from the 12 human PDA cell
lines. (E) Heatmap representation of unsupervised hierarchical clustering of mouse PSCs based on their global transcriptional profile. Scale bar
indicates Pearson correlation coefficient. Control refers to control media, which was DMEM supplemented with 5% FBS. (F) Heatmap representation of
differentially expressed genes from PSCs in Group 1 and Group 2. Selected genes in each group are listed. Scale bar indicates standardized expression
value. (G) GSEA plot evaluating Hallmark Inflammatory Response genes based on their expression in Group 2 versus Group 1 cultures. (H–I) GSEA plots
evaluating the iCAF and myCAF gene signatures in Group 2 versus Group 1 cultures.
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Figure 1—figure supplement 1. A secretory phenotype of p63-positive PDA cells that promotes inflammatory gene expression changes in CAFs in
vitro. (A) Bar chart shows RT-qPCR analysis for TP63 isoforms in MIAPaca2, BxPC3, T3M4 and KLM1 PDA cell lines. (B) Luciferase-based quantification of
mouse PSC proliferation in Matrigel following four days of culture with conditioned media from the indicated human PDA cell lines. Mean+ SEM is
shown. n = 5 technical repeats (C) Representative bright-field images from (B). Scale bar indicates 200 mm. (D) Table summarizing GSEA evaluating
Hallmark gene sets for their enrichment in Group 2 versus Group 1 cultures. Gene sets with a FWER p value < 0.05 are shown. (E) Bar chart showing RT-
qPCR analysis for iCAF markers (IL6, CXCL1, LIF) following culture of human PSCs in Matrigel for four days with conditioned media from the indicated
human cell lines. Mean+ SEM is shown. n = 3. ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for multiple comparisons. ns, not
significant.
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Figure 2. p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro. (A) Schematic of workflow for generating
conditioned media from SUIT2-empty and SUIT2-p63 cells and subsequent analysis of PSC cultures. (B–C) Bar charts showing RT-qPCR analysis for iCAF
markers (Il6, Cxcl1, Lif) following culture of 2 mouse PSC lines in Matrigel for four days with the indicated conditioned media. (D) RT-qPCR analysis for
the iCAF markers (IL6, CXCL1, LIF) following culture of human PSCs in Matrigel for four days with the indicated conditioned media. (E) Mouse mM1
organoids were infected with a p63 cDNA or empty vector control. Bar chart shows RT-qPCR analysis for iCAF markers (Il6, Cxcl1, Lif) following culture
of a mouse PSC line in Matrigel for four days in the indicated conditioned medias. (F) Schematic of workflow for generating conditioned media from
KLM1-Cas9 cells infected with p63 sgRNAs (sgTP63#2 and sgTP63#4) or a control (sgNEG) and subsequent analysis of PSC cultures. (G–H) Bar chart
showing RT-qPCR analysis for iCAF markers (Il6, Cxcl1, Lif) following culture of mouse PSCs in Matrigel for four days with the indicated conditioned
media. (I) RT-qPCR analysis for iCAF markers (IL6, CXCL1, LIF) following culture of human PSCs in Matrigel for four days with the indicated conditioned
media. For all experiments, control media represents DMEM supplemented with 5% FBS. Mean+ SEM is shown. Results are presented as the mean of
three technical replicates and are representative of n = 3 biological replicates. For B-E, ***p<0.001, **p<0.01, *p<0.05 by Student’s t-test and for G-I,
***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for multiple comparisons.
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Figure 2—figure supplement 1. p63 expression in PDA cells drives a secretory phenotype that induces iCAF formation in vitro. (A–B) Bar charts
showing RT-qPCR analysis for myCAF markers (Acta2, Ctgf) following culture of the two mouse PSC lines in Matrigel for four days with conditioned
Figure 2—figure supplement 1 continued on next page
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Figure 2—figure supplement 1 continued
media from SUIT2-empty or SUIT2-p63 cells. (C) Luciferase-based quantification of mouse PSC proliferation in Matrigel. (D) Representative bright-field
images from (C). Scale bar indicates 500 mm. (E) Bar charts showing RT-qPCR analysis for myCAF markers (ACTA2, CTGF) following culture of human
PSCs in Matrigel for four days with conditioned media from SUIT2-empty or SUIT2-p63 cells. (F) Bar chart shows RT-qPCR analysis for myCAF markers
(Acta2, Ctgf) following culture of mouse PSCs in conditioned media from mM1-empty or mM1-p63 cells. (G) Representative western blot analysis for
ACTB and p63 following p63 knock out in KLM1-Cas9 and T3M4-Cas9 cells. (H) Competition based GFP depletion assays of KLM1-Cas9 cells (left
panel) or T3M4-Cas9 cells (right panel) following infection with the indicated sgRNAs linked to GFP. (I) GSEA plot evaluating the Squamous-PDA
Identity signature following doxycycline-inducible knock out of p63 and subsequent RNA-seq analysis KLM1 cells. The Squamous-PDA Identity
signature was defined previously (Somerville et al., 2018). (J–K) Metagene representation (J) and browser track examples (K) of H3K27ac signal at
Squamous Elements in p63-negative and p63-positive PDA cells. Normal organoids: hN34, hN35; PDA organoids: hF3, hT85; PATU: PATU8988S. (L–N)
Bar charts showing RT-qPCR analysis for myCAF marker genes following culture of two mouse PSC cell lines (L and M) or human PSCs (N) in Matrigel
for four days with conditioned media from KLM1-Cas9 cells infected with the indicated sgRNA. (O) Luciferase-based quantification of mouse PSC
proliferation in Matrigel cultured with conditioned media from KLM1-Cas9 cells infected with sgRNAs targeting TP63 or control (sgNEG). (P)
Representative bright-field images from (O). Scale bar indicates 500 mm. For all experiments control media represents DMEM supplemented with 5%
FBS. Matrigel only represents conditioned media from Matrigel cultured with control media only. Mean+ SEM is shown. n = 3. For A, B, E and F,
***p<0.001, **p<0.01, *p<0.05 by Student’s t-test and for C, ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for multiple
comparisons. ns, not significant.
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Figure 3. Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor microenvironment. (A–I)
SUIT2-empty and SUIT2-p63 PDA cells harboring a luciferase transgene were transplanted into the pancreas of NSG mice. (A–B) Quantification of
tumor volume (A) and images of tumors (B) on day 25 post-transplantation. (C) Experimental workflow for RNA-seq analysis of bulk tumor tissue. (D–E)
Heatmap representations of differentially expressed genes that unambiguously map to (D) the human genome and therefore are derived from human
cancer cells or (E) the mouse genome and therefore are derived from mouse stromal cells. Selected genes in each group are listed. Scale bar indicates
standardized expression value. (F) Ontology analysis of the 500 significantly up-regulated mouse genes using Metascape. GO terms are ranked by their
significance (p value) and the most significant terms (-log10 p value > 15) are highlighted. (G) GSEA plot evaluating the iCAF signature in the mouse
stromal compartment of SUIT2-p63 versus SUIT2-empty tumors. (H) Quantification of flow cytometry analysis of CD45+CD11b+Ly6G+ neutrophils and
CD45+CD11b+F4/80+ macrophages from bulk tumor tissues from SUIT2 xenografts. n = 5 mice per group. ***p<0.001 by Student’s t-test. (I)
Figure 3 continued on next page
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Figure 3 continued
Representative flow cytometry plots from (H). (J–K) KPC mM1 organoids with a p63 cDNA or empty vector control and transplanted to the pancreas of
C57BL6 mice. (J) Quantification of flow cytometry analysis of CD45+ cells in the tumors. n = 4–5 mice per group. ***p<0.001 by Student’s t-test. (K)
Representative flow cytometry plots from (J). TCRb refers to T cell receptor b.
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Figure 3—figure supplement 1. Ectopic expression of p63 in PDA cells promotes inflammation-associated transcriptional changes in the tumor
microenvironment. (A) Luciferase-based quantification of SUIT2-empty and SUIT2-p63 cell proliferation in vitro. Mean ± SEM values are shown. n = 6
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Figure 3—figure supplement 1 continued
technical repeats. (B) Quantification of the bioluminescence signal following transplantation of SUIT2- empty or SUIT2-p63 cells to the pancreas of NSG
mice. Mean ± SEM in shown. Mice were imaged every two days between day seven and 23 post-transplantation. n = 5 mice per group. (C)
Quantification of p63 expression by immunohistochemical staining of tumors. p value determined by Student’s t-test. (D) Representative images from
(C). MT, Masson’s trichrome. Scale bar indicates 50 mm. (E) Representative western blot analysis for ACTB and p63 in mM1-empty or mM1-p63 cells. (F)
Bar chart showing RT-qPCR analysis for squamous markers (TP63, Krt5, Krt6a and S100a2) and Il1a in mM1-empty and mM1-p63 cells. Mean+ SEM is
shown. n = 3. (G) Representative bright-field images of mM1 organoid cultures. (H) Quantification of in vitro cell growth measured by CellTiter-Glo.
RLU, relative luminescence units. (I–J) Quantification of tumor volume (I) and images of tumors (J) on day 45 post-transplantation of mM1 organoids to
the pancreas of C57BL/6 mice. ***p<0.001 by Student’s t-test. (K) Representative images from (J). MT, Masson’s trichrome. Scale bar indicates 50 mm.
(L) GSEA plot evaluating the Squamous-PDA Identity signature (Somerville et al., 2018) within the human cancer cell compartment of p63-positive
versus negative tumors. (M) GSEA plot evaluating the myCAF signature in the mouse stromal compartment of SUIT2-p63 versus SUIT2-empty tumors.
(N–P) RT-qPCR analysis of flow-sorted tumor samples. (N) Schematic of experimental workflow. (O) Representative flow cytometry plots showing the
gating strategy for enriching human cancer cells, mouse fibroblasts and mouse immune cells. (P) Bar chart showing RT-qPCR analysis for the indicated
genes in the indicated sorted fraction and tumor samples. ***p<0.001, **p<0.01, *p<0.05 by two-way ANOVA with Sidak’s test for multiple
comparisons. (QT) Orthotopic tumors derived from hF3 (squamous/basal) and hF27 (progenitor/classical) human tumor organoids were subjected to
RNA-seq analysis of the bulk tumor tissue. (Q) TP63 and IL1A expression in the human cancer cell compartment of the tumors. (R) GSEA plot evaluating
the Squamous PDA identity signature in the human cancer cell compartment of hF3 versus hF27 tumors. (S) GSEA plot evaluating the iCAF signature in
the mouse stromal compartment of hF3 versus hF27 tumors. (T) Expression levels of genes preferentially expressed on neutrophils in the mouse stromal
cell compartment of the hF3 and hF27 tumors. Data are from Miyabayashi et al (currently under review). (U) ELISA of IL-6 in the plasma of mice from (J)
at end point. n = 4–5 mice per group. ***p<0.001 by Student’s t-test.
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Figure 4. Knockout of p63 in an orthotopic PDA tumor model attenuates stromal inflammation. (A–E) KLM1-Cas9 cells expressing a luciferase
transgene were infected with two independent p63 or control (sgNEG) sgRNAs and transplanted to the pancreas of NSG mice. (A) Quantification of
Figure 4 continued on next page
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Figure 4 continued
bioluminescence signal. Mean ± SEM is shown. Mice were imaged every four days between day 7 and day 57 post-transplantation. n = 4–5 mice per
group. *p<0.05 by two-way ANOVA with Sidak’s test for multiple comparisons. (B) Representative images at day 7 and day 57 post-transplantation from
(A). (C) Table summarizing the median time mice from each group were sacrificed and the tumor volume at endpoint. Endpoint was determined as a
bioluminescence signal >3109 p/s for each individual mouse. **p<0.01 by log rank (Mantel-Cox) test. (D) Quantification of p63 expression as
determined by immunohistochemical staining of tumors from the indicated experimental groups. n = 4–5 mice per group. ***p<0.001 by one-way
ANOVA with Tukey’s test for multiple comparisons. (E) Representative images from (D). Scale bar indicates 50 mm. (F) Schematic of experimental
workflow and sorting strategy for enriching for human cancer cells, mouse fibroblasts and mouse immune cells and subsequent RNA-seq analysis. (G–I)
Heatmap representations of differentially expressed genes from the human cancer cell compartment (G), mouse fibroblast compartment (H) and mouse
immune compartment (I) and the indicated tumor samples. Selected genes in each group are listed. Scale bar indicates standardized expression value.
(J) GSEA plot evaluating the iCAF signature in the mouse fibroblast compartment of p63-positive versus control (sgNEG) tumors. (K) Ontology analysis
of the 463 significantly down-regulated mouse genes from immune compartment using Metascape. GO terms are ranked by their significance (p value)
and the most significant term (-log10 p value > 15) is highlighted. (L–N) SUIT2-empty or SUIT2-p63 cells were cultured in isolation or together with
mouse PSCs in Matrigel for four days before conditioned media was harvested and used for a trans-well migration assay with freshly isolated mouse
neutrophils. (L) Schematic of experimental workflow. (M) Quantification of trans-well neutrophil migration in the indicated media conditions as
determined by confocal imaging. Mean+ SEM is shown. Results are presented as the mean number of invading neutrophils per 10 random fields for
each condition and are representative of n = 3 biological replicates. ***p<0.001, **p<0.01 by two-way ANOVA with Sidak’s test for multiple
comparisons. All significant interactions are shown. (N) Representative confocal images from (M).
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Figure 4—figure supplement 1. Knockout of p63 in an orthotopic PDA tumor model attenuates the inflammatory signature of fibroblasts and immune
cells. (A) Western blot analysis for HSC70 and p63 in the KLM1-Cas9 cells following p63 knock out with CRISPR. (B) Representative images from
Figure 4—figure supplement 1 continued on next page
Somerville et al. eLife 2020;9:e53381. DOI: https://doi.org/10.7554/eLife.53381 13 of 20
Research article Cancer Biology Human Biology and Medicine
Figure 4—figure supplement 1 continued
Figure 4D. Scale bar indicates 50 mm. MT, Masson’s trichrome. (C) GSEA plot evaluating the 459 significantly down-regulated human genes based on
their expression in TP63high versus TP63low PDA patient samples from the study by Bailey et al. (2016). Patients were designated as TP63high or TP63low
as described in Somerville et al. (2018). (D) GSEA plot evaluating the myCAF signature in FACS-purified fibroblasts from p63-positive (sgNEG) or p63
knockout tumors. (E–H) Quantification of LY6G (E) and MPO (G) expression as determined by immunofluorescence staining of tumors from the
indicated experimental groups. n = 4–5 mice per group. ***p<0.001, **p<0.01 by Student’s t-test. Representative images for LY6G (F) and MPO (H) are
shown. Scale bar indicates 100 mm and applies to all images. (I) Bar charts show RT-qPCR analysis for the iCAF markers (Il6, Cxcl1, Lif; left panel) and
myCAF markers (Acta2, Ctgf; right panel) in the indicated culture conditions. Mean+ SEM is shown. n = 3. ***p<0.001, **p<0.01 by Student’s t-test. (J)
Quantification of trans-well neutrophil migration stimulated by murine (mCXCL1) or human CXCL1 (hCXCL1) as determined by confocal imaging. These
experiments were performed alongside the SUIT2-empty or SUIT2-p63 cells co-culture experiments shown in the main figure as positive controls. Mean
+ SEM is shown. Results are presented as the mean number of invading neutrophils per 10 random fields for each condition and are representative of
n = 3 biological replicates. ***p<0.001, **p<0.01 by two-way ANOVA with Sidak’s test for multiple comparisons. (K–M) Conditioned media was
harvested from SUIT2-empty or SUIT2-p63 cells (K), AsPC1-empty or AsPC1-p63 cells (L), or KLM1-Cas9 cells infected with sgRNAs targeting TP63 or a
control sgRNA (sgNEG) (M) after four days and used for trans-well migration assays with freshly isolated mouse neutrophils in the presence of a CXCL1
blocking antibody or IgG control. Bar charts show quantification of trans-well neutrophil migration in the indicated media conditions as determined by
confocal imaging. Mean+ SEM is shown. n = 3. ***p<0.001, **p<0.01, *p<0.05 by two-way ANOVA with Sidak’s test for multiple comparisons. ns, not
significant.
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Figure 5. p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells. (A–B) GSEA plots evaluating
the indicated Hallmark gene signatures upon p63 expression in SUIT2 cells. (C) Scatter plot shows the mean log2 fold change of expressed genes upon
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Figure 5 continued
p63 expression in SUIT2 cells. Genes with a mean log2 fold change >1 in this dataset and the BxPC3+sgTP63 dataset (Figure 5—figure supplement
1B) that are also found in the gene signatures shown in A and B are highlighted along with the rank. Data are from Somerville et al. (2018). (D)
Heatmap shows gene expression changes in those genes shown in (C) in the indicated cell lines following p63 over-expression (left panel) or knockout/
knockdown (right panel). Scale bar indicates mean log2 fold change versus control. (E) ChIP-seq profiles of p63 (top track) and H3K27ac (bottom four
tracks) following p63 knockout in BxPC3 cells or overexpression in SUIT2 cells surrounding the IL1 locus. The H3K27ac regions identified as a super
enhancer by ROSE analysis are indicated along with the positions of sgRNAs targeting this enhancer used for experiments shown in (F) and (I). (F) RT-
qPCR analysis for IL1A and IL1B in SUIT2-empty or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated
sgRNAs. The positions of the sgRNAs targeting the IL1 super enhancer are shown in (E). (G–H) ELISA for IL-1a and IL-1b from conditioned media
harvested from KLM1-Cas9 cells infected with the indicated sgRNA (G) or from SUIT2-empty and SUIT2-p63 cells (H). (I) ELISA for IL-1a in SUIT2-empty
or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated sgRNAs. (J–K) Bar charts showing RT-qPCR analysis
for iCAF markers (Il6, Cxcl1, Lif) following culture of clones of two mouse PSC lines from which the IL-1 receptor was clonally knocked out with CRISPR
in Matrigel for four days with conditioned media from SUIT2-empty or SUIT2-p63 cells. (L) Bar charts showing RT-qPCR analysis for iCAF markers (Il6,
Cxcl1, Lif) following culture of PSCs in Matrigel for four days with the conditioned media harvested from cells shown in (I). For all experiments, control
media represent DMEM supplemented with 5% FBS. Mean+ SEM is shown. For RT-qPCR experiments, results are presented as the mean of three
technical replicates and are representative of n = 3 biological replicates and ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for
multiple comparisons. For each ELISA experiment, n = 3 biological replicates and ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Tukey’s test
for multiple comparisons. ns = not significant.
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Rank Hallmark Gene Set NES FWER p value 
1 TNFA_SIGNALING_VIA_NFKB +2.48 0
2 P53_PATHWAY +2.12 0
3 KRAS_SIGNALING_UP +2.11 0.001
4 INFLAMMATORY_RESPONSE +2.01 0.005
5 HYPOXIA +2.00 0.005
6 IL6_JAK_STAT3_SIGNALING +1.95 0.01
7 EPITHELIAL_MESENCHYMAL_TRANSITION +1.94 0.01
8 MYC_TARGETS_V2 +1.85 0.037
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Figure 5—figure supplement 1. p63 activates enhancer elements and transcription of genes encoding pro-inflammatory cytokines in PDA cells. (A)
Table shows evaluation of the indicated Hallmark gene sets by GSEA upon p63 expression in SUIT2 cells. Gene sets are ranked by their NES score and
Figure 5—figure supplement 1 continued on next page
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Figure 5—figure supplement 1 continued
only those with a FWER p value < 0.05 are shown. (B) Scatter plot shows the mean log2 fold change of expressed genes upon p63 knock out in BxPC3
cells. Genes with a mean log2 fold change >1 in this dataset and the SUIT2-p63 dataset (Figure 5C) that are also found in the gene signatures shown in
Figure 5A and Figure 5B are highlighted along with the rank. Data are from Somerville et al. (2018). (C) Representative western blot analysis for
ACTB, p63 and Cas9 in KLM1 and T3M4 cells lentivirally transduced with a doxycycline-inducible Cas9 vector and the indicated sgRNA. (D) ChIP-seq
profiles of p63 in BxPC3 cells surrounding the genes shown in Figure 5D. (E–H) Scatter plots showing enhancers ranked by intensity in SUIT2-empty (E),
SUIT2-p63 (F) and BxPC3-Cas9 cells transduced with a control sgRNA (G) or a sgRNA targeting TP63 (H). Shaded box highlights the number of super
enhancers identified and the super enhancer associated with the IL1 locus is highlighted along with its rank. (I) RTqPCR analysis for S100A2 in SUIT2-
empty or SUIT2-p63 cells infected with dCas9 fused with the KRAB repression domain and the indicated sgRNAs. Mean+ SEM is shown. n = 3.
***p<0.001, **p<0.01, *p<0.05 versus empty control by one-way ANOVA with Dunnett’s test for multiple comparisons. (J–K) Bar charts showing RT-
qPCR analysis for the indicated myCAF markers (Acta2, Ctgf) following culture of two mouse PSC lines from which the IL1 receptor was clonally
knocked out with CRISPR in Matrigel for four days with conditioned media from SUIT2-empty or SUIT2-p63 cells. (L) Bar charts showing RT-qPCR
analysis for myCAF markers (Acta2, Ctgf) following culture of PSCs in Matrigel for four days with the conditioned media harvested from cells shown in
Figure 5I. Mean+ SEM is shown. n = 3. ***p<0.001, **p<0.01, *p<0.05 by one-way ANOVA with Dunnett’s test for multiple comparisons.
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Figure 6. Squamous trans-differentiation of PDA cells correlates with increased inflammatory fibroblasts and neutrophil infiltration in patient samples.
(A) Quantification of IL1A mRNA levels in the indicated studies. Each dot represents one patient sample, and patients were stratified as TP63high or
TP63low as described in Somerville et al. (2018). (B–D) Single cell RNA-seq data from 24 primary PDA tumor and 11 normal pancreas samples from the
study by Peng et al. (2019). (B) 24 primary PDA tumor samples ranked by mean TP63 expression levels across all cell types. Patients were stratified as
TP63high (n = 4) or TP63low (n = 4) as shown. (C) Expression of squamous genes in ductal cells from TP63high or TP63low PDA patient samples from (B).
(D) Expression of inflammatory genes (IL6, CXCL1 and LIF) in stellate cells and fibroblast cells from TP63high or TP63low PDA patient samples from (B).
Each dot represents a single cell and the four patient samples were pooled for this analysis. (E–F) Multiplex immunofluorescent staining of primary
pancreatic cancer tumor from the Rapid Autopsy Program. (E) Quantification of p63, MPO, aSMA and MUC1 in p63-negative (p63neg, n = 6) and p63-
positive (p63pos, n = 6) samples. (F) Representative images of a p63-positive PDA tumor stained with DAPI (blue), MPO (orange), aSMA (white), MUC1
(green), p63 (red), and overlaid (merge). The images were collected from the same tumor area, but over multiple rounds of iterative staining. Scale bar
indicates 20 mm. For (A), (C) and (D) ***p<0.001, **p<0.01 by Student’s t-test. ns, not significant.
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Figure 6—figure supplement 1. p63 expression in PDA cells is associated with inflammatory CAF induction and neutrophil infiltration in patient
samples. (A–C) Single cell RNA-seq data from 24 primary PDA tumor and 11 normal pancreas samples from the study by Peng et al. (2019). (A) UMAP
representation of cell clusters identified from analysis of 57,530 cells from all samples (15,544 cells from normal tissue and 41,986 from tumor tissue).
Cluster were re-derived from the Peng et al study. (B) TP63 expression across cell types shown in (A) from normal samples (left) or tumor samples
(right). (C) Expression of myofibroblastic genes (ACTA2 and CTGF) in stellate cells and fibroblast cells from TP63high or TP63low PDA patient samples.
Each dot represents a single cell and the four patient samples were pooled for this analysis. ***p<0.001 by Student’s t-test. (D) Multiplex
immunoflourescent staining of primary pancreatic cancer tumor from the Rapid Autopsy Program. Representative images of a p63-negative PDA tumor
stained with DAPI (blue), MPO (orange), aSMA (white), Muc1 (green), P63 (red), overlaid (merge). The images were collected from the same area but
over multiple rounds of iterative staining. Scale bar indicates 20 mm.
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